About: Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population
Creator	Graff, Claus Holst, Anders Isaksen, Jonas Kanters, Jørgen Nielsen, Jonas Pietersen, Adrian
Source	MedRxiv
abstract	Background: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have recently been suggested as treatment for the current Corona Virus Disease 2019 (COVID-19) pandemic. However, despite their long-term use and only few case reports on adverse effects, CQ and HCQ are listed as a known risk of the lethal ventricular arrhythmia Torsade de Pointes and their cardiac safety profile is being questioned. Thus, we aimed to investigate the electrocardiographic and mortality effects of CQ and HCQ in a primary care population. Methods: We used Danish health care registers and electrocardiograms (ECGs) from primary care to define three studies. 1) A paired study of subjects with ECGs before and during use of CQ/HCQ, 2) a matched ECG study of subjects taking CQ/HCQ compared to controls, and 3) a mortality study on people taking HCQ matched to control. In both matched studies, we adjusted for connective tissue diseases, use of QT-prolonging drugs, and cardiac disease. We used the QTc interval as the marker for electrocardiographic safety. In the mortality study, cases were followed from first claimed prescription until 300 days after estimated completion of the last prescription. 95% confidence intervals follow estimates in parenthesis. Results: Use of CQ was associated with a 5.5 (0.7;10) ms increase in QTc in the paired study (n=10). In the matched study (n=28, controls=280), QTc was insignificantly increased in subjects taking CQ by 4.7 (-3.4;13) ms. With a {Delta}QTc of 1.0 (-5.6;7.5), use of HCQ was not associated with an increased QTc in the paired study (n=32). In the matched study (n=172, controls=1,720), QTc also was not different between groups (p=0.5). In the mortality study (n=3,368), use of HCQ was associated with a hazard ratio of 0.67 (0.43;1.05). Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1101/2020.06.19.20135475
has license	medrxiv
sha1sum (hex)	952a7e8021a1ffa14ed62e8176141fb5321385e5
schema:url	https://doi.org/10.1101/2020.06.19.20135475
resource representing a document's title	Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population
resource representing a document's body	covid:952a7e8021a1ffa14ed62e8176141fb5321385e5#body_text
is schema:about of	named entity 'VIRUS DISEASE' named entity 'THEIR' named entity 'BACKGROUND' named entity 'CURRENT' covid:arg/952a7e8021a1ffa14ed62e8176141fb5321385e5 named entity 'Virus' named entity 'electrocardiographic' named entity 'pandemic' named entity 'ventricular arrhythmia' named entity '2019' named entity 'However' named entity 'Corona Virus Disease 2019' named entity 'adverse effects' named entity 'HCQ' named entity 'electrocardiographic' named entity 'HCQ' named entity 'Chloroquine' named entity 'COVID-19' named entity 'primary care' named entity 'Chloroquine' named entity 'WHO' named entity '1.1' named entity 'ischemic heart disease' named entity 'HBV' named entity 'HCQ' named entity 'HCQ' named entity 'HCQ' named entity 'peer review' named entity 'ATC code' named entity 'HCQ' named entity 'SLE' named entity 'PR interval' named entity 'malaria prophylaxis' named entity 'CC-BY-ND' named entity 'Corona Virus Disease' named entity 'SLE' named entity 'ICD-8' named entity 'HCQ' named entity 'Ischemic heart disease' named entity 'loop diuretics' named entity 'CC-BY-ND' named entity 'QT-prolongation' named entity 'hypertension' named entity 'Chloroquine' named entity '0.51' named entity 'CC-BY-ND' named entity 'viral replication' named entity 'chloroquine' named entity 'HCQ' named entity 'Arrhythmias' named entity 'Hydroxychloroquine' named entity 'Danish Data Protection Agency' named entity 'CC-BY-ND' named entity 'HCQ' named entity 'SLE' named entity 'medRxiv' named entity 'Torsade de Pointes' named entity 'medRxiv' named entity 'HCQ' named entity 'peer review' named entity 'TdP' named entity 'CC-BY-ND' named entity 'diabetes' named entity 'medRxiv' named entity 'HCQ' named entity 'study population' named entity 'medRxiv' named entity 'peer review' named entity 'COVID' named entity 'chloroquine' named entity 'HCQ' named entity 'ventricular septal defect' named entity 'ICD-10' named entity 'Rheumatoid Arthritis' named entity 'QRS' named entity 'calcium' named entity 'Hydroxychloroquine' named entity 'cirrhosis' named entity 'calcium blockers' named entity 'congestive heart failure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software